Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.
2.
3.

The role of immunity in protection from mucosal SIV infection in macaques.

Bergmeier LA, Wang Y, Lehner T.

Oral Dis. 2002;8 Suppl 2:63-8. Review.

PMID:
12164663
4.

Anti-HIV and -SIV immunity in the vagina.

Miller CJ, Lü FX.

Int Rev Immunol. 2003 Jan-Feb;22(1):65-76. Review.

PMID:
12710504
5.

Relevance of studying T cell responses in SIV-infected rhesus macaques.

Valentine LE, Watkins DI.

Trends Microbiol. 2008 Dec;16(12):605-11. doi: 10.1016/j.tim.2008.08.010. Epub 2008 Oct 27. Review.

6.

Nonhuman primate models for HIV/AIDS vaccine development.

Sui Y, Gordon S, Franchini G, Berzofsky JA.

Curr Protoc Immunol. 2013 Oct 1;102:Unit 12.14.. doi: 10.1002/0471142735.im1214s102. Review.

7.

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G.

Adv Exp Med Biol. 1996;397:7-13. Review.

8.

Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

Demberg T, Robert-Guroff M.

Int Rev Immunol. 2009;28(1):20-48. doi: 10.1080/08830180802684331. Review.

9.

The role of MHC class I gene products in SIV infection of macaques.

Silver ZA, Watkins DI.

Immunogenetics. 2017 Aug;69(8-9):511-519. doi: 10.1007/s00251-017-0997-3. Epub 2017 Jul 10. Review.

10.

HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection.

Lynch RM, Yamamoto T, McDermott AB.

Curr Opin HIV AIDS. 2013 Jul;8(4):288-94. doi: 10.1097/COH.0b013e328361cfe8. Review.

11.

Use of nonhuman primate models to develop mucosal AIDS vaccines.

Genescà M, Miller CJ.

Curr HIV/AIDS Rep. 2010 Feb;7(1):19-27. doi: 10.1007/s11904-009-0035-7. Review.

12.

CD4+ T cell responses to simian immunodeficiency virus.

Mills KH, Jones WC.

Curr Top Microbiol Immunol. 1994;188:161-73. Review. No abstract available.

PMID:
7924425
13.

Class II-Restricted CD8s: New Lessons Violate Old Paradigms.

Migueles SA, Connors M.

Immunity. 2016 Oct 18;45(4):712-714. doi: 10.1016/j.immuni.2016.10.004. Review.

14.

Th17 cells in pathogenic simian immunodeficiency virus infection of macaques.

Cecchinato V, Franchini G.

Curr Opin HIV AIDS. 2010 Mar;5(2):141-5. doi: 10.1097/COH.0b013e32833653ec. Review.

15.

Mucosal Vaccination for Prevention of HIV Infection and AIDS.

Aldovini A.

Curr HIV Res. 2016;14(3):247-59. Review.

PMID:
26957199
16.

Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines.

Klasse PJ, Moore JP.

Retrovirology. 2012 Oct 1;9:80. doi: 10.1186/1742-4690-9-80. Review.

17.

Characterization of an effective CTL response against HIV and SIV infections.

Genescà M.

J Biomed Biotechnol. 2011;2011:103924. doi: 10.1155/2011/103924. Epub 2011 Sep 29. Review.

18.

Oral mucosal immunity and HIV/SIV infection.

Lü FX, Jacobson RS.

J Dent Res. 2007 Mar;86(3):216-26. Review.

PMID:
17314252
19.

Pirate primates in uncharted waters: lymphocyte transfers in unrelated, MHC-matched macaques.

Burwitz BJ, Greene JM, O'Connor DH.

Curr HIV Res. 2009 Jan;7(1):51-6. Review.

20.

Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.

Belyakov IM, Ahlers JD.

Curr Top Microbiol Immunol. 2012;354:157-79. doi: 10.1007/82_2010_119. Review.

PMID:
21203884

Supplemental Content

Support Center